# Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

> **NCT03736369** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 263 (actual)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** DWP14012 40mg
- **DRUG:** DWP14012 40mg placebo
- **DRUG:** Esomeprazole 40mg
- **DRUG:** Esomeprazole 40mg placebo

## Key facts

- **NCT ID:** NCT03736369
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2019-08-07
- **Final completion:** 2019-08-07
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2020-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03736369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03736369, "Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03736369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*